French Biotech to Develop Anti-Cancer Drugs with Measles Virus

Scientists are constantly searching for new strategies to fight cancer. But sometimes, it’s not about finding a brand-new treatment, but modifying existing forms of treatment to make them more effective.

At the Institut Pasteur in Paris, France, scientists from the viral genomics and vaccination unit have developed new technologies to create a more potent anti-cancer drug. They entered an exclusive licensing agreement with its spin-off company, Oncovita, earlier this week.